Business Description
Ascendis Pharma AS
NAICS : 325411
ISIN : BRA1SNBDR008
Description
Financial Strength
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.39 | |||||
Equity-to-Asset | -0.42 | |||||
Debt-to-Equity | -2.1 | |||||
Debt-to-EBITDA | -1.95 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 3.09 | |||||
Beneish M-Score | -2.53 | |||||
WACC vs ROIC |
Growth Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 213.9 | |||||
3-Year EBITDA Growth Rate | 6.7 | |||||
3-Year EPS without NRI Growth Rate | -6.4 | |||||
3-Year FCF Growth Rate | -8.9 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 60.29 |
Momentum Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 92.27 | |||||
9-Day RSI | 88.4 | |||||
14-Day RSI | 86.21 | |||||
6-1 Month Momentum % | -6.82 | |||||
12-1 Month Momentum % | 35.44 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 0.74 | |||||
Quick Ratio | 0.44 | |||||
Cash Ratio | 0.31 | |||||
Days Inventory | 1667.94 | |||||
Days Sales Outstanding | 39.68 | |||||
Days Payable | 845.1 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -1.7 | |||||
Shareholder Yield % | -1.96 |
Profitability Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 85.58 | |||||
Operating Margin % | -110.4 | |||||
Net Margin % | -153.32 | |||||
FCF Margin % | -130.92 | |||||
ROA % | -59.82 | |||||
ROIC % | -68.89 | |||||
3-Year ROIIC % | -338.01 | |||||
ROC (Joel Greenblatt) % | -213.74 | |||||
ROCE % | -95.3 |
GF Value Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 25.26 | |||||
EV-to-EBIT | -24.41 | |||||
EV-to-Forward-EBIT | -13.75 | |||||
EV-to-EBITDA | -24.87 | |||||
EV-to-Forward-EBITDA | -14.48 | |||||
EV-to-Revenue | 26.76 | |||||
EV-to-Forward-Revenue | 14.92 | |||||
EV-to-FCF | -20.21 | |||||
Earnings Yield (Greenblatt) % | -4.07 | |||||
FCF Yield % | -5.23 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Ascendis Pharma AS Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil R$) | 1,716.723 | ||
EPS (TTM) (R$) | -46.933 | ||
Beta | 0.02 | ||
Volatility % | 33.32 | ||
14-Day RSI | 86.21 | ||
14-Day ATR (R$) | 0.656806 | ||
20-Day SMA (R$) | 46.6155 | ||
12-1 Month Momentum % | 35.44 | ||
52-Week Range (R$) | 27.62 - 53.35 | ||
Shares Outstanding (Mil) | 57.35 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 4 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Ascendis Pharma AS Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Ascendis Pharma AS Stock Events
Event | Date | Price(R$) | ||
---|---|---|---|---|
No Event Data |
Ascendis Pharma AS Frequently Asked Questions
What is Ascendis Pharma AS(BSP:A1SN34)'s stock price today?
When is next earnings date of Ascendis Pharma AS(BSP:A1SN34)?
Does Ascendis Pharma AS(BSP:A1SN34) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |